The challenge of implementing genetic tests with clinical utility while avoiding unsound applications

[1]  E. Rutgers,et al.  The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. , 2011, European journal of cancer.

[2]  Alberto Cambrosio,et al.  Cancer clinical trials in the era of genomic signatures: Biomedical innovation, clinical utility, and regulatory-scientific hybrids , 2011, Social studies of science.

[3]  M. Cornel,et al.  Genetic testing and common disorders in a public health framework , 2011, European Journal of Human Genetics.

[4]  A. Cambon-Thomsen,et al.  Genetic Testing and Common Disorders: How to Assess Relevance and Possibilities , 2011 .

[5]  Pascal Borry,et al.  Statement of the ESHG on direct-to-consumer genetic testing for health-related purposes , 2010, European Journal of Human Genetics.

[6]  Jörg Schmidtke,et al.  The EuroGentest Clinical Utility Gene Cards , 2010, European Journal of Human Genetics.

[7]  F. Collins.  Has the revolution arrived? , 2010, Nature.

[8]  Brigitte Schlegelberger,et al.  Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2) , 2010, European Journal of Human Genetics.

[9]  Judy H. Cho,et al.  Finding the missing heritability of complex diseases , 2009, Nature.

[10]  Rebekah Rasooly,et al.  The Genomic Applications in Practice and Prevention Network , 2009, Genetics in Medicine.

[11]  Jorge Sequeiros,et al.  Genetic horoscopes: is it all in the genes? Points for regulatory control of direct-to-consumer genetic testing , 2009, European Journal of Human Genetics.

[12]  G. Ginsburg.  Genomic Medicine: ‘Grand challenges’ in the translation of genomics to human health , 2008, European Journal of Human Genetics.

[13]  M. W. Foster,et al.  Out of sequence: how consumer genomics could displace clinical genetics , 2008, Nature Reviews Genetics.

[14]  Paul G Shekelle,et al.  Delivery of genomic medicine for common chronic adult diseases: a systematic review. , 2008, JAMA.

[15]  S. Straus,et al.  Lost in knowledge translation: Time for a map? , 2006, The Journal of continuing education in the health professions.

[16]  J. Emery,et al.  How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom , 2005, Genetics in Medicine.

[17]  J. Cassiman.  Research network: EuroGentest – a European Network of Excellence aimed at harmonizing genetic testing services , 2005, European Journal of Human Genetics.

[18]  E. Dequeker,et al.  Towards quality assurance and harmonization of genetic testing services in the European Union , 2004, Nature Biotechnology.

[19]  P. Kovanen,et al.  New approaches to investigating heterogeneity in complex traits , 2003, Journal of medical genetics.

[20]  J. Boffa.  Is there a doctor in the house? , 2002, Australian and New Zealand journal of public health.

[21]  F. Collins,et al.  Implications of the Human Genome Project for medical science. , 2001, JAMA.

[22]  A. Cambon-Thomsen,et al.  Background Document to the ESHG recommendations on genetic testing and common disorders , 2011 .

[23]  M. Khoury,et al.  Evaluation of the validity and utility of genetic testing for rare diseases. , 2010, Advances in experimental medicine and biology.

[24]  Additional protocol to the convention on human rights and biomedicine, concerning genetic testing for health purposes. , 2008, Revista de derecho y genoma humano = Law and the human genome review.

[25]  Provision of genetic services in Europe: current practices and issues , 2003, European Journal of Human Genetics.